SentreHEART has elected medical device industry veteran Richard M Ferrari to its board of directors. Ferrari is currently the managing director and co-founder of De Novo Ventures and brings a wealth of strategic and operational knowledge SentreHEART’s board.
“Richard is a visionary business leader with more than 35 years of experience in the medical device industry. His successful track record and proven ability to create transformational value in both start-up and public companies will be an incredible asset, as we bring to market innovative solutions for patients with atrial fibrillation,” said Russell Seiber, SentreHEART founder and chief executive officer.
Ferrari served as chief executive officer of Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters, which was eventually acquired by Boston Scientific. His most recent success as chief executive officer was with CardioThoracic Systems, which was acquired by Guidant.
During the past 15 years, Ferrari has also held numerous board positions, including at Spinal Modulations, which was acquired by St Jude Medical and FoxHollow Technologies, which was taken public.
“With the recent Food and Drug Administration approval of the aMAZE trial, SentreHEART may be able to offer patients with persistent atrial fibrillation an exciting new therapy option, with the potential of becoming a new standard of care,” said Ferrari. “I look forward to working with the board of directors and executive leadership to bring continued success in product innovation, clinical development and commercialisation.”
